Cherimolacyclopeptide F
Internal ID | 9aa0dea8-7b9c-432c-b156-f7380b4c32a6 |
Taxonomy | Organic acids and derivatives > Carboxylic acids and derivatives > Amino acids, peptides, and analogues > Peptides > Oligopeptides |
IUPAC Name | (3S,6S,12S,15S,18S,24S,30S)-18-[(2S)-butan-2-yl]-15-[(4-hydroxyphenyl)methyl]-12-(2-methylpropyl)-3,24-bis(2-methylsulfanylethyl)-1,4,10,13,16,19,22,25,28-nonazatricyclo[28.3.0.06,10]tritriacontane-2,5,11,14,17,20,23,26,29-nonone |
SMILES (Canonical) | CCC(C)C1C(=O)NC(C(=O)NC(C(=O)N2CCCC2C(=O)NC(C(=O)N3CCCC3C(=O)NCC(=O)NC(C(=O)NCC(=O)N1)CCSC)CCSC)CC(C)C)CC4=CC=C(C=C4)O |
SMILES (Isomeric) | CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N1)CCSC)CCSC)CC(C)C)CC4=CC=C(C=C4)O |
InChI | InChI=1S/C45H69N9O10S2/c1-7-27(4)38-43(62)50-32(23-28-12-14-29(55)15-13-28)40(59)51-33(22-26(2)3)45(64)54-19-9-11-35(54)42(61)49-31(17-21-66-6)44(63)53-18-8-10-34(53)41(60)47-24-36(56)48-30(16-20-65-5)39(58)46-25-37(57)52-38/h12-15,26-27,30-35,38,55H,7-11,16-25H2,1-6H3,(H,46,58)(H,47,60)(H,48,56)(H,49,61)(H,50,62)(H,51,59)(H,52,57)/t27-,30-,31-,32-,33-,34-,35-,38-/m0/s1 |
InChI Key | MSOKWXAMNQYLTA-DEAILCOJSA-N |
Popularity | 1 reference in papers |
Molecular Formula | C45H69N9O10S2 |
Molecular Weight | 960.20 g/mol |
Exact Mass | 959.46088178 g/mol |
Topological Polar Surface Area (TPSA) | 315.00 Ų |
XlogP | 2.70 |
Atomic LogP (AlogP) | 0.19 |
H-Bond Acceptor | 12 |
H-Bond Donor | 8 |
Rotatable Bonds | 12 |
There are no found synonyms. |
![2D Structure of Cherimolacyclopeptide F 2D Structure of Cherimolacyclopeptide F](https://plantaedb.com/storage/docs/compounds/2023/07/cherimolacyclopeptide-f.jpg)
Target | Value | Probability (raw) | Probability (%) |
---|---|---|---|
Human Intestinal Absorption | + | 0.9210 | 92.10% |
Caco-2 | - | 0.8643 | 86.43% |
Blood Brain Barrier | - | 0.7500 | 75.00% |
Human oral bioavailability | - | 0.6143 | 61.43% |
Subcellular localzation | Mitochondria | 0.5620 | 56.20% |
OATP2B1 inhibitior | - | 0.7112 | 71.12% |
OATP1B1 inhibitior | + | 0.8236 | 82.36% |
OATP1B3 inhibitior | + | 0.9270 | 92.70% |
MATE1 inhibitior | - | 0.8200 | 82.00% |
OCT2 inhibitior | - | 0.8000 | 80.00% |
BSEP inhibitior | + | 0.9294 | 92.94% |
P-glycoprotein inhibitior | + | 0.7530 | 75.30% |
P-glycoprotein substrate | + | 0.8858 | 88.58% |
CYP3A4 substrate | + | 0.6809 | 68.09% |
CYP2C9 substrate | - | 0.6108 | 61.08% |
CYP2D6 substrate | - | 0.8030 | 80.30% |
CYP3A4 inhibition | - | 0.8970 | 89.70% |
CYP2C9 inhibition | - | 0.8954 | 89.54% |
CYP2C19 inhibition | - | 0.8596 | 85.96% |
CYP2D6 inhibition | - | 0.8850 | 88.50% |
CYP1A2 inhibition | - | 0.9642 | 96.42% |
CYP2C8 inhibition | + | 0.7395 | 73.95% |
CYP inhibitory promiscuity | - | 0.9892 | 98.92% |
UGT catelyzed | + | 0.7000 | 70.00% |
Carcinogenicity (binary) | - | 0.8200 | 82.00% |
Carcinogenicity (trinary) | Non-required | 0.6746 | 67.46% |
Eye corrosion | - | 0.9906 | 99.06% |
Eye irritation | - | 0.9056 | 90.56% |
Skin irritation | - | 0.7734 | 77.34% |
Skin corrosion | - | 0.9035 | 90.35% |
Ames mutagenesis | - | 0.6354 | 63.54% |
Human Ether-a-go-go-Related Gene inhibition | - | 0.4548 | 45.48% |
Micronuclear | + | 0.7200 | 72.00% |
Hepatotoxicity | + | 0.5282 | 52.82% |
skin sensitisation | - | 0.8847 | 88.47% |
Respiratory toxicity | + | 0.7778 | 77.78% |
Reproductive toxicity | + | 0.9222 | 92.22% |
Mitochondrial toxicity | + | 0.8750 | 87.50% |
Nephrotoxicity | + | 0.4881 | 48.81% |
Acute Oral Toxicity (c) | III | 0.6663 | 66.63% |
Estrogen receptor binding | + | 0.8203 | 82.03% |
Androgen receptor binding | + | 0.7205 | 72.05% |
Thyroid receptor binding | + | 0.5208 | 52.08% |
Glucocorticoid receptor binding | - | 0.4755 | 47.55% |
Aromatase binding | + | 0.6562 | 65.62% |
PPAR gamma | + | 0.7556 | 75.56% |
Honey bee toxicity | - | 0.7371 | 73.71% |
Biodegradation | - | 0.7500 | 75.00% |
Crustacea aquatic toxicity | - | 0.5100 | 51.00% |
Fish aquatic toxicity | + | 0.7643 | 76.43% |
Proven Targets:
CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
---|---|---|---|---|---|
No proven targets yet! |
Predicted Targets (via Super-PRED):
CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
---|---|---|---|---|
CHEMBL2581 | P07339 | Cathepsin D | 99.85% | 98.95% |
CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 98.54% | 96.09% |
CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 97.70% | 90.08% |
CHEMBL6175 | Q9H3R0 | Lysine-specific demethylase 4C | 97.03% | 96.69% |
CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 96.16% | 94.45% |
CHEMBL4261 | Q16665 | Hypoxia-inducible factor 1 alpha | 95.08% | 85.14% |
CHEMBL5896 | O75164 | Lysine-specific demethylase 4A | 95.08% | 99.09% |
CHEMBL2069156 | Q14145 | Kelch-like ECH-associated protein 1 | 95.02% | 82.38% |
CHEMBL5966 | P55899 | IgG receptor FcRn large subunit p51 | 94.91% | 90.93% |
CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 93.74% | 97.25% |
CHEMBL226 | P30542 | Adenosine A1 receptor | 93.45% | 95.93% |
CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 93.16% | 90.71% |
CHEMBL3524 | P56524 | Histone deacetylase 4 | 92.92% | 92.97% |
CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 92.43% | 95.89% |
CHEMBL3137262 | O60341 | LSD1/CoREST complex | 91.26% | 97.09% |
CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 90.98% | 91.11% |
CHEMBL1902 | P62942 | FK506-binding protein 1A | 90.63% | 97.05% |
CHEMBL2693 | Q9UIQ6 | Cystinyl aminopeptidase | 90.18% | 97.64% |
CHEMBL4616 | Q92847 | Ghrelin receptor | 90.18% | 92.00% |
CHEMBL5697 | Q9GZT9 | Egl nine homolog 1 | 89.07% | 93.40% |
CHEMBL4478 | Q00975 | Voltage-gated N-type calcium channel alpha-1B subunit | 88.27% | 97.14% |
CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 87.15% | 95.56% |
CHEMBL3807 | P17706 | T-cell protein-tyrosine phosphatase | 86.26% | 93.00% |
CHEMBL3310 | Q96DB2 | Histone deacetylase 11 | 86.20% | 88.56% |
CHEMBL4071 | P08311 | Cathepsin G | 85.82% | 94.64% |
CHEMBL4633 | P22001 | Voltage-gated potassium channel subunit Kv1.3 | 85.48% | 100.00% |
CHEMBL1978 | P11511 | Cytochrome P450 19A1 | 85.37% | 91.76% |
CHEMBL2189110 | Q15910 | Histone-lysine N-methyltransferase EZH2 | 85.19% | 97.50% |
CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 85.16% | 100.00% |
CHEMBL1937 | Q92769 | Histone deacetylase 2 | 85.00% | 94.75% |
CHEMBL2288 | Q13526 | Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | 84.62% | 91.71% |
CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 83.92% | 95.89% |
CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 83.77% | 96.90% |
CHEMBL4461 | Q9NTG7 | NAD-dependent deacetylase sirtuin 3 | 83.65% | 94.36% |
CHEMBL217 | P14416 | Dopamine D2 receptor | 83.28% | 95.62% |
CHEMBL5203 | P33316 | dUTP pyrophosphatase | 83.24% | 99.18% |
CHEMBL255 | P29275 | Adenosine A2b receptor | 82.84% | 98.59% |
CHEMBL4208 | P20618 | Proteasome component C5 | 82.20% | 90.00% |
CHEMBL2443 | P49862 | Kallikrein 7 | 82.05% | 94.00% |
CHEMBL3202 | P48147 | Prolyl endopeptidase | 81.64% | 90.65% |
CHEMBL333 | P08253 | Matrix metalloproteinase-2 | 80.87% | 96.31% |
CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 80.50% | 92.88% |
CHEMBL2535 | P11166 | Glucose transporter | 80.20% | 98.75% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
PubChem | 101773878 |
NPASS | NPC275110 |
LOTUS | LTS0009598 |
wikiData | Q105171309 |